Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

SHE:002262 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	5,791	5,638	4,976	4,255	3,919	3,344
Other Revenue	59.61	59.61	65.63	43.49	16.53	16.99
Revenue	5,851	5,698	5,042	4,299	3,936	3,361
Revenue Growth (YoY)	12.08%	13.01%	17.29%	9.22%	17.09%	-18.99%
Cost of Revenue	1,531	1,546	1,403	1,037	932.68	843.14
Gross Profit	4,320	4,152	3,638	3,262	3,003	2,518
Selling, General & Admin	2,342	2,244	1,944	1,847	1,743	1,443
Research & Development	644.24	595.65	549.32	454.25	351.73	245.86
Other Operating Expenses	68.62	65.65	60.2	57.46	54.04	45.61
Operating Expenses	3,083	2,939	2,569	2,360	2,156	1,737
Operating Income	1,237	1,213	1,070	901.63	847.28	781.53
Interest Expense	-3.52	-4.03	-4.16	-4.95	-5.06	-1.59
Interest & Investment Income	93.35	87.82	74.85	61.8	53.92	48.32
Currency Exchange Gain (Loss)	0.17	0.17	0.41	0.91	-1.14	-0.38
Other Non Operating Income (Expenses)	3.32	-1.9	-0.74	-3.19	-1.62	1.43
EBT Excluding Unusual Items	1,330	1,295	1,140	956.2	893.38	829.31
Impairment of Goodwill	-	-	-	-	-	-0.82
Gain (Loss) on Sale of Assets	0.2	0.29	0.15	0.37	-0.24	-0.15
Asset Writedown	0.65	0.07	0.22	-0.28	-0.74	-0.21
Other Unusual Items	2.19	0.99	28.32	33.62	23.38	22.35
Pretax Income	1,333	1,297	1,169	989.91	915.78	850.48
Income Tax Expense	156.49	155.9	134.4	109.82	117.75	123.37
Earnings From Continuing Operations	1,177	1,141	1,034	880.09	798.02	727.1
Minority Interest in Earnings	2.19	2.77	2.67	20.62	-0.24	1.72
Net Income	1,179	1,144	1,037	900.71	797.78	728.82
Net Income to Common	1,179	1,144	1,037	900.71	797.78	728.82
Net Income Growth	9.70%	10.29%	15.12%	12.90%	9.46%	9.88%
Shares Outstanding (Basic)	1,008	1,012	1,007	1,012	1,010	1,012
Shares Outstanding (Diluted)	1,008	1,012	1,007	1,012	1,010	1,012
Shares Change (YoY)	-0.70%	0.53%	-0.53%	0.22%	-0.24%	0.72%
EPS (Basic)	1.17	1.13	1.03	0.89	0.79	0.72
EPS (Diluted)	1.17	1.13	1.03	0.89	0.79	0.72
EPS Growth	10.47%	9.71%	15.73%	12.66%	9.72%	9.09%
Free Cash Flow	543.13	466.07	634.31	533.27	495.01	979.74
Free Cash Flow Per Share	0.54	0.46	0.63	0.53	0.49	0.97
Dividend Per Share	0.360	0.360	0.320	0.200	0.200	0.100
Dividend Growth	12.50%	12.50%	60.00%	-	100.00%	-
Gross Margin	73.83%	72.87%	72.17%	75.88%	76.30%	74.92%
Operating Margin	21.14%	21.29%	21.22%	20.97%	21.53%	23.25%
Profit Margin	20.15%	20.07%	20.57%	20.95%	20.27%	21.68%
Free Cash Flow Margin	9.28%	8.18%	12.58%	12.41%	12.58%	29.15%
EBITDA	1,392	1,364	1,205	1,025	959.57	878.36
EBITDA Margin	23.79%	23.95%	23.90%	23.84%	24.38%	26.13%
D&A For EBITDA	155.16	151.16	135.14	123.12	112.28	96.83
EBIT	1,237	1,213	1,070	901.63	847.28	781.53
EBIT Margin	21.14%	21.29%	21.22%	20.97%	21.53%	23.25%
Effective Tax Rate	11.74%	12.02%	11.50%	11.09%	12.86%	14.51%
Revenue as Reported	5,851	5,698	5,042	4,299	3,936	3,361

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.